We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Psychiatry

Psychiatry

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
newsadolescentsmetformin

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

By MedXY|Nov 17, 2025

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipola

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
newsadolescentsbipolar disorder

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

By MedXY|Nov 17, 2025

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with se

Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort
newspublic healthrecovery

Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort

By MedXY|Nov 14, 2025

A longitudinal, nationally representative cohort study found that within-person transition from current to former cigarette smoking was associated with a 30–43% higher odds of sustained recovery from other substance use disorders, supportin

Collaborative Care for OUD in Primary Care Reduces Opioid Use: Cluster RCT Shows Added Benefit from an OUD-Focused Model
Family Medicine & Nutritioncollaborative careopioid use disorder

Collaborative Care for OUD in Primary Care Reduces Opioid Use: Cluster RCT Shows Added Benefit from an OUD-Focused Model

By MedXY|Nov 14, 2025

A pragmatic cluster randomized trial found that adding OUD-specific components to collaborative care in primary care clinics reduced days of opioid use more than collaborative care for mental health alone, without clear additional mental he

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial
newspharmacogenomicstreatment-resistant depression

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial

By MedXY|Nov 14, 2025

In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), wi

High‑Intensity Interval Training Fails to Rescue Hippocampal Integrity in Adults With Cannabis Use Disorder — but Exercise Is Feasible and May Reduce Craving
Neurologycannabis use disorderexercise

High‑Intensity Interval Training Fails to Rescue Hippocampal Integrity in Adults With Cannabis Use Disorder — but Exercise Is Feasible and May Reduce Craving

By MedXY|Nov 14, 2025

A randomized trial in adults with moderate–severe cannabis use disorder found 12 weeks of supervised HIIT did not improve a composite MRI measure of hippocampal integrity versus strength/resistance training; exercise participation was feasi

Brief Cognitive Behavioral Therapy Cuts Suicide Attempts in High‑Risk US Military Personnel and Veterans: MSPIRE RCT Confirms Prior Findings
newssuicide preventionveterans

Brief Cognitive Behavioral Therapy Cuts Suicide Attempts in High‑Risk US Military Personnel and Veterans: MSPIRE RCT Confirms Prior Findings

By MedXY|Nov 14, 2025

A 2‑arm randomized trial (MSPIRE) found brief cognitive behavioral therapy (BCBT) significantly reduced suicide attempts versus present‑centered therapy in suicidal military personnel and veterans, despite comparable reductions in suicidal

Distinct and Shared Risk Profiles for Suicide Attempt Versus Suicide: Insights from Danish Registers and Genomic Data
newsPolygenic Scoressuicide

Distinct and Shared Risk Profiles for Suicide Attempt Versus Suicide: Insights from Danish Registers and Genomic Data

By MedXY|Nov 14, 2025

A large Danish register and genetic study shows overlapping but distinct environmental and genetic risk factors for nonfatal suicide attempts and death by suicide, with chronic and functional health problems linked more to attempts and seve

Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery
Dermatologycortisoloxytocin

Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery

By MedXY|Nov 14, 2025

A double‑blind RCT in 160 healthy adults found that intranasal oxytocin combined with structured positive interaction and daily physical intimacy (affectionate touch, sex) was associated with reduced cortisol and modestly faster dermatologi

Sexual Assault and the Long Shadow of the Body: Higher 5‑Year Risk of Functional Somatic Disorders and Chronic Widespread Pain
newscohort study

Sexual Assault and the Long Shadow of the Body: Higher 5‑Year Risk of Functional Somatic Disorders and Chronic Widespread Pain

By MedXY|Nov 14, 2025

A prospective Danish cohort found that adults reporting lifetime sexual assault had substantially higher 5‑year incidence of functional somatic disorders—especially multiorgan FSD and chronic widespread pain—after adjustment for psychosocia

Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?
HIV/AIDSHIVmodafinil

Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?

By MedXY|Nov 12, 2025

Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction

Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients
HIV/AIDSdepressionHIV

Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients

By MedXY|Nov 12, 2025

Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.

Not All Antidepressants Are the Same: Differential Cardiometabolic and Physiological Effects from a Large Network Meta‑analysis
Cardiologyantidepressantscardiometabolic risk

Not All Antidepressants Are the Same: Differential Cardiometabolic and Physiological Effects from a Large Network Meta‑analysis

By MedXY|Nov 10, 2025

A 151‑trial network meta‑analysis of 58,534 participants shows marked differences among 30 antidepressants in weight, blood pressure, heart rate, lipids, glucose and liver enzymes; findings support individualized choice and targeted baselin

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening
GastroenterologyARFIDscreening

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening

By MedXY|Nov 10, 2025

A 2023 population survey of 4,002 adults in the UK and US found that positive screens for avoidant/restrictive food intake disorder (ARFID) were common among people with disorders of gut–brain interaction (DGBI) and associated with greater

Gamma (40 Hz) Sensory Flicker Shows Promise for Insomnia but Needs Controlled Trials
Neurology40 Hzgamma entrainment

Gamma (40 Hz) Sensory Flicker Shows Promise for Insomnia but Needs Controlled Trials

By MedXY|Nov 9, 2025

A prospective observational study of 37 adults with insomnia reports high adherence and no serious adverse events with 40 Hz light–sound flicker and sleep-diary improvements in sleep onset, arousals, and total sleep time; limitations includ

How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target
Internal Medicineaerobic exercisechronic illness

How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target

By MedXY|Nov 8, 2025

A meta-analysis of 36 RCTs (n=2,500) found aerobic exercise significantly reduces depressive symptoms in people with chronic illness (Hedges’ g -0.73). A weekly dose of ≈405 MET‑min (≈120–135 min of moderate aerobic activity) reaches

Persistent Depressive Symptoms After MCI Strongly Predict Progression to Alzheimer’s Disease
NeurologyAlzheimer's diseasedepression

Persistent Depressive Symptoms After MCI Strongly Predict Progression to Alzheimer’s Disease

By MedXY|Nov 5, 2025

In an ADNI longitudinal cohort, persistently elevated depressive symptoms over 36 months after MCI diagnosis were associated with a dose‑dependent, substantially higher hazard of conversion to Alzheimer’s disease over long-term follow-up.

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset
NeurologyAlzheimer's diseaseEarly-onset dementia

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset

By MedXY|Nov 4, 2025

In two large Alzheimer cohorts, a history of depression, anxiety, or PTSD and an increased number of psychiatric comorbidities were associated with earlier age at AD symptom onset by up to ~7–8 years for multi-morbidity.

Circadian Dysregulation and Executive Dysfunction in Wolfram Syndrome: Toward Chrono‑Diagnosis and Chronotherapy
Neurologycircadian rhythms

Circadian Dysregulation and Executive Dysfunction in Wolfram Syndrome: Toward Chrono‑Diagnosis and Chronotherapy

By MedXY|Nov 4, 2025

Emerging evidence links WFS1-driven ER stress to serotonergic/cholinergic disruption, executive dysfunction, and circadian dysregulation in Wolfram syndrome. This article synthesizes recent data, outlines chrono‑informed clinical assessment

Recent Advances in Alcohol Metabolism: from the Gut to the Brain
Gastroenterologyalcohol metabolismbariatric surgery

Recent Advances in Alcohol Metabolism: from the Gut to the Brain

By MedXY|Nov 4, 2025

This article reviews the latest findings on human alcohol metabolism, covering evolutionary biology, systemic and brain-specific pathways, genetic and physiological modulators, clinical implications of metabolic variability, and emerging th

Prev
11 / 19
1…910111213…19
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles